The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 10 January 2006, www.theannals.com, DOI 10.1345/aph.1G170.
 The Annals of Pharmacotherapy: Vol. 40, No. 2, pp. 286-289. DOI 10.1345/aph.1G170
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maier, S. K
Right arrow Articles by Hammond, J. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maier, S. K
Right arrow Articles by Hammond, J. M

DRUG INFORMATION ROUNDS

OBJETIVO: Evaluar el uso de lenalidomida en el manejo de mieloma múltiple y síndrome mielodisplásico.

FUENTES DE DATOS: Se realizó una revisión de la literatura a través de MEDLINE (1966-agosto de 2005), en el Índice de Citación Científica (1980-agosto de 2005), y en las Actas de la Sociedad Americana de Hematología (2000-2004).

SÍNTESIS DE DATOS: Se han sintetizado nuevos análogos de talidomida que son más potentes y menos tóxicos. La lenalidomida, CC-5103, se encuentra en estudios de la Fase III para el manejo de mieloma múltiple y síndrome mielodisplásico. Estudios en Fase II demostraron la eficacia de lenalidomida en pacientes refractarios a talidomida. Aún está por probarse el potencial total de este fármaco, pero los datos preliminares lucen prometedores.

CONCLUSIONES: Lenalidomida es un inmunomodulador potente que ofrece varios mecanismos de acción y utilidad terapéutica en el manejo de mieloma múltiple, síndrome mielodisplásico, y otras malignidades.

www.theannals.com, DOI 10.1345/aph.1G170



This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maier, S. K
Right arrow Articles by Hammond, J. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maier, S. K
Right arrow Articles by Hammond, J. M

homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.